Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis

被引:173
作者
Strbian, D. [1 ]
Sairanen, T. [1 ]
Meretoja, A. [1 ]
Pitkaniemi, J. [3 ]
Putaala, J. [1 ,3 ]
Salonen, O. [2 ]
Silvennoinen, H. [2 ]
Kaste, M. [1 ]
Tatlisumak, T. [1 ]
机构
[1] Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00290 Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, Dept Radiol, FIN-00290 Helsinki, Finland
[3] Univ Helsinki, Dept Publ Hlth, FIN-00290 Helsinki, Finland
基金
芬兰科学院;
关键词
ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; INTRAVENOUS THROMBOLYSIS; CANADIAN ALTEPLASE; ECASS; THERAPY;
D O I
10.1212/WNL.0b013e3182267b8c
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: To assess the impact of symptomatic intracerebral hemorrhage (sICH) on outcome of thrombolysis-treated ischemic stroke patients, as additional to recognized prognosticators. Methods: The study cohort included 985 ischemic stroke patients treated with IV thrombolysis at the Helsinki University Central Hospital (1995-2008). In a multivariable model adjusted for baseline stroke severity, age, onset-to-treatment time, baseline glucose, hyperdense cerebral artery sign, and early infarct signs on baseline imaging, and prior modified Rankin Scale (mRS), we calculated risk ratios (RRs) of patients with sICH (separately per Safe Implementation of Thrombolysis in Stroke[SITS]-Monitoring Study, European Cooperative Acute Stroke Study II [ECASS-II], and National Institute of Neurological Disorders and Stroke [NINDS] definitions) for poor 3-month outcome (mRS 3-6) and mortality. Receiver operating characteristic (ROC) curve and integrated discrimination improvement (IDI) evaluated impact of sICH on outcome. Internal cross-validation of the model was done with bootstrap statistics. Results: The frequency of sICH was 2.1% (SITS), 7.0% (ECASS-II), and 9.4% (NINDS). RRs for poor and fatal outcome, respectively, were 1.7 and 4.8 (SITS), 1.6 and 3.8 (ECASS-II), and 1.6 and 3.4 (NINDS). In IDI analyses, sICH improved prediction model for 3-month mRS of 3-6 and 4-6, respectively, by 1.4% and 3.0% (SITS), 4.0% and 5.9% (ECASS-II), and 4.7% and 6.1% (NINDS). In case of 3-month mRS 5-6 and mortality, it was 6.1% and 5.3% (SITS), 11.3% and 9.3% (ECASS-II), and 10.3% and 8.0% (NINDS). ROC analysis revealed similar results. Conclusions: Patients with sICH have increased risk of poor and fatal outcome. Compared with recognized stroke prognosticators, contribution of sICH is smaller. Definition-wise, ECASS-II- and NINDS-based sICH contribute relatively more; ECASS-II has the largest contribution to worst outcomes. Neurology (R) 2011; 77: 341-348
引用
收藏
页码:341 / 348
页数:8
相关论文
共 20 条
[1]   Asymptomatic hemorrhage after thrombolysis may not be benign - Prognosis by hemorrhage type in the Canadian Alteplase for Stroke Effectiveness Study registry [J].
Dzialowski, Imanuel ;
Pexman, J. H. Warwick ;
Barber, Philip A. ;
Demchuk, Andrew M. ;
Buchan, Alastair M. ;
Hill, Michael D. .
STROKE, 2007, 38 (01) :75-79
[2]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251
[3]  
HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
[4]  
Hacke W, 2004, LANCET, V363, P768
[5]   Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke [J].
Hacke, Werner ;
Kaste, Markku ;
Bluhmki, Erich ;
Brozman, Miroslav ;
Davalos, Antoni ;
Guidetti, Donata ;
Larrue, Vincent ;
Lees, Kennedy R. ;
Medeghri, Zakaria ;
Machnig, Thomas ;
Schneider, Dietmar ;
von Kummer, Ruediger ;
Wahlgren, Nils ;
Toni, Danilo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) :1317-1329
[6]   A METHOD OF COMPARING THE AREAS UNDER RECEIVER OPERATING CHARACTERISTIC CURVES DERIVED FROM THE SAME CASES [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1983, 148 (03) :839-843
[7]   Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study [J].
Hill, MD ;
Buchan, AM .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (10) :1307-1312
[8]   Do not wait, act now [J].
Kaste, Markku .
STROKE, 2007, 38 (12) :3119-3120
[9]   Disappearing hyperdense middle cerebral artery sign in ischaemic stroke patients treated with intravenous thrombolysis: clinical course and prognostic significance [J].
Kharitonova, T. ;
Thoren, M. ;
Ahmed, N. ;
Wardlaw, J. M. ;
von Kummer, R. ;
Thomassen, L. ;
Wahlgren, N. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (03) :273-278
[10]   FACTORS RELATED TO INTRACRANIAL HEMATOMA FORMATION IN PATIENTS RECEIVING TISSUE-TYPE PLASMINOGEN-ACTIVATOR FOR ACUTE ISCHEMIC STROKE [J].
LEVY, DE ;
BROTT, TG ;
HALEY, EC ;
MARLER, JR ;
SHEPPARD, GL ;
BARSAN, W ;
BRODERICK, JP .
STROKE, 1994, 25 (02) :291-297